Blaze Bioscience, Inc., a Seattle, WA-based biotechnology company, raised $9m in Series B financing.
The round, which brought total funds since inception to $19m, was raised from new and existing individual investors.
The company intends to use the funds for the clinical development of its Tumor PaintTM product candidate, BLZ-100, and Optide drug candidates as part of the collaboration and option agreement entered into with Fred Hutchinson Cancer Research Center in June of this year.
Co-founded by Dr. Jim Olson of Fred Hutchinson Cancer Research Center and President and Chief Executive Officer Heather Franklin, a former senior business executive at ZymoGenetics, Inc., Blaze Bioscience develops BLZ-100, a combination of an Optide, which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range.
It is under development for cancer surgery in multiple solid tumor types.
FinSMEs
03/12/2013
Related News
22/02/2013: Blaze Bioscience Completes $8.5M Series A Financing